Opko Health, Inc. Announces Fourth Quarter And Full Year 2013 Results

OPKO Health, Inc. (NYSE:OPK), a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013.

“Work has been continuing in our research laboratories on a program to utilize specific oligonucleotides to up regulate protein production. A pre-IND meeting has been scheduled with FDA in connection with the development of the first product to treat Dravet’s Syndrome, a congenital condition characterized by chronic seizures.”

Help employers find you! Check out all the jobs and post your resume.